Feature | Cath Lab | May 06, 2021| By Dave Fornell, Editor

SCAI 2021 Late-breaking Clinical Study Results

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions Virtual Conference, which took place April 28 - May 1. Sessions share the latest advances in interventional cardiology and featured late-breaking clinical research. Find the entire virtual meeting program and links to the archived on-demand sessions at www.scai.org/scai2021.

SCAI 2021 Late-Breaking Studies:

Update on the North American COVID-19 Myocardial Infarction (NACMI) Registry — one-third of patients die, effects large percentage of minorities, 20% do not have cuplit lesions — Presented by Payam Dehghani, M.D., University of Saskatchewan

SCAI Shock Classification for Mortality Risk Stratification: Survey of Published Evidence. Presented by Jacob Jentzer, M.D., Mayo Clinic.

Final Results From The National Cardiogenic Shock Initiative — Survival With Impella Increased to 71%. Presented by Babar Basir, D.O., Henry Ford Health System.

Establishing the Optimal Duration of DAPT After PCI in High-Risk TWILIGHT-like patients with Acute Coronary Syndrome. Presented by Haoyu Wang, Fuwai Hospital, National Center for Cardiovascular Diseases

Study reveals need for equitable access of TAVR minimally invasive heart procedures. Presented by Ashwin Nathan, M.D., Hospital of the University of Pennsylvania

Study reveals patients in ISCHEMIA trial only represent small fraction of heart disease patients undergoing intervention, calling into question the study's application in real-world practice. Presented by Saurav Chatterjee, Northwell Health.

Safety and Efficacy of the Second Generation Robotic-Assisted System for Percutaneous Coronary Intervention: Final Results of the Multicenter PRECISION GRX Study in a real-world population across a spectrum of lesion complexity. Presented by Ehtisham Mahmud, M.D., UCS San Diego Health

Hospital-Level Percutaneous Coronary Intervention Performance with Simulated Risk Avoidance Strategies Did Not Necessarily Help Hospital Performance Scores. Presented by Ashwin Nathan, M.D., Hospital of the University of Pennsylvania

Radial Hemostasis Time Cut by 50 Percent With StatSeal in Combination With TR Band —reduces time to hemostasis following cardiac catheterization procedures and improves cath lab efficiency. Presented by Arnold Seto, M.D., UCI Health.

Breakthrough technology provides advanced, non-invasive treatment option for patients with congenital heart disease — One-year Results of the Harmony Transcatheter Pulmonary Valve Trial . Presented by Thomas Jones, M.D., Seattle Children’s Hospital

Global registry Shows Longer Stent Minimizes Procedure Complications in Sinus Venosus Atrial Septal Defects. Presented by Dr. Eric Rosenthal, Guy’s and St. Thomas NHS Foundation Trust in London, England

 

Other SCAI 202I News:

VIDEO: The Impact of COVID-19 on Heart Attack Patients — Interview with Payam Dehghani, M.D.

VIDEO: Radial Hemostasis Reduced by 50 Percent With StatSeal in Combination With TR Band — Interview with Arnold Seto, M.D., and Jordan Safirstein, M.D

Young African Americans With Coronary Disease Impacted by Non-traditional Risk Factors

VIDEO: Socioeconomic and Geographic Access to TAVR Programs is Limited — Interview with Ashwin Nathan M.D.

VIDEO: Final Results of the National Cardiogenic Shock Initiative Show 71 Percent Survival — Interview with Bill O'Neill, M.D.

VIDEO: Avoiding Higher Risk Cath Lab Patients May Not Improve Outcomes Scores — Interview with Ashwin Nathan M.D., 

Find more SCAI news and video

 

Related Late-Breaking Cardiology Presentations:

ACC 2021 Late-Breaking Presentations Announced

SCAI Announces 2020 Late-breaking Clinical Studies

 

TCT 2020 Late-breaking Study Presentations

American Heart Association 2020 Late-breaking Trial Presentations 

 

 

#SCAI2021

Related Content

Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium.

Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium. 

News | Cardiovascular Clinical Studies | January 27, 2021
January 27, 2021 — A New York Institute of Technology research te
Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di